According to the hormonal receptor status, BC patients were classified into luminal A (ER/PR+, HER2−; 8/80 (10%)), luminal B (ER/PR+, HER2+; 52/80 (65%)), and triple negative (ER−/PR−/HER2−; 20/80 (25%)). The gene discussed is NR4A1; the disease is breast cancer.